Analysis of Oligonucleotide Impurities Using Single Quadrupole Mass Spectrometer

Importance of the Topic

Oligonucleotide therapeutics represent an emerging class of drugs that demand rigorous impurity analysis to ensure safety and efficacy. Accurate detection and quantitation of sequence variants are essential in development and quality control stages.

Objectives and Study Overview

This study demonstrates a workflow for identifying and quantifying n-1 and n-3 sequence impurities in a model oligonucleotide (FLP) using a Shimadzu LCMS-2050 single quadrupole mass spectrometer and LabSolutions Insight Biologics software.

Methodology

• Reversed-phase ion-pair chromatography with 100 mmol/L HFIP and 10 mmol/L TEA gradient on a Shim-pack Scepter Claris C18 column.
• Mass detection in negative ESI/APCI mode over m/z 650–2000.
• Software-based sequence definition to combine multivalent and isotopic ions into single component chromatograms.
• Quantitation by correlating UV peak area with MS-derived component fractions through a defined calculation formula.

Instrumentation Used

• HPLC System: Nexera XS inert
• Mass Spectrometer: LCMS-2050 single quadrupole
• Column: Shim-pack Scepter Claris C18-120 (100 × 2.1 mm, 1.9 µm)
• Software: LabSolutions Insight Biologics

Main Results and Discussion

The n-3 impurity was baseline separated, while the n-1 impurity co-eluted with the main peak but was successfully deconvoluted by MS data. FLP calibration (1–50 µmol/L) yielded r² ≥ 0.999. Both impurities were detected at ≥ 0.25% relative levels (0.05 µmol/L) with linearity r² ≥ 0.999.

Benefits and Practical Applications

• Enables sensitive quantitation of well-separated and co-eluted oligonucleotide impurities.
• Simplifies QC workflows using a single-quadrupole MS.
• Combines UV and MS data for comprehensive purity assessment.

Future Trends and Applications

Advances in high-throughput MS, AI-driven data processing, and integration with higher-resolution instruments will further improve sensitivity and throughput. Expansion to modified and larger oligonucleotides is anticipated.

Conclusion

The LCMS-2050 paired with LabSolutions Insight Biologics delivers a robust platform for impurity profiling in oligonucleotide therapeutics, achieving reliable detection and quantitation even for co-eluted sequence variants.

Reference

1. Ryutaro Takamine, Takao Yamaguchi, Challenges of Impurities Analysis in Manufacturing Therapeutic Oligonucleotides, J. Mass Spectrom. Soc. Jpn., 2023, 71(2), 51–54.